Collaborate

Below is a listing for all eMERGE studies currently submitted to and/or accessible in dbGaP.

Accession Number Study Description Molecular Data Type Release Date
phs000203 Case/control study aiming to identify the generic variants mediating susceptibility to peripheral arterial disease (PAD). N= 3,337. Whole Genome Genotyping 11/05/2010
phs000188 Case set of participants exploring QRS duration on the electrocardiogram. N= 3,021. Whole Genome Genotyping 10/08/2011
phs000408 Case set containing data from the Geisinger eMERGE Genome-wide Association Study of Obesity Project. N= 962. Whole Genome Genotyping 12/06/2011
phs000387 Case set exploring the genetic determinants of Abdominal Aortic Aneurysm. N= 910. Whole Genome Genotyping 12/19/2011
phs000381 Control set of data from participants enrolled from community-based primary care clinics of Geisinger Health System. N= 1,231. Whole Genome Genotyping 12/19/2011
phs000380 Case set containing data from the Geisinger eMERGE Genome Wide Association Studies of Obesity (Metabochip). N= 982. Whole Genome Genotyping 01/12/2012
phs000237 Case/control study of data exploring the genetic determinants and race differences in prevalence of Type 2 Diabetes. N= 3,563. Whole Genome Genotyping 04/22/2012
phs000494 Cohort studies of data from participants enrolled across seven cohorts at Cincinnati Children’s Hospital. N= 4,562. Whole Genome Genotyping 07/23/2012
phs000297 Case/control study exploring the genetic determinants of resistant hypertension. N= 5,281. Whole Genome Genotyping 09/26/2012
phs000495 Prospective longitudinal study of participants enrolled in the Gene Partnership at Boston Children’s Hospital. N= 1,024. Whole Genome Genotyping 08/30/2013
phs000490 Case/control study of data exploring the genetic causes of complex pediatric disorders. N= 7,431. Whole Genome Genotyping 10/02/2013
phs000170 Case/control study exploring the genetic determinants of cataract and lipid abnormalities. N= 3,989. Whole Genome Genotyping 03/09/2015
phs000948 Cohort study containing data from participants, aged 50-65, enrolled at GroupHealth Cooperative. N= 1,968. Whole Exome Genotyping 08/28/2015
phs000957 Case/control exome chip study for Abdominal Aortic Aneurysm and extreme obesity. N= 9,212. Whole Exome Genotyping 11/16/2015
phs000944 Cross-sectional study of data from a subset of participants enrolled in the Partners Healthcare Biobank. N= 4,929. Whole Genome Genotyping 03/07/2016
phs000961 Prospective case/control cohort study of participants enrolled in the Columbia University GENIE study. N= 3,065. Whole Genome Genotyping 06/07/2016
phs000360 Case/control study exploring the genetics determinants of five individual phenotypes. N= 18,663. Targeted Genomic Sequencing 08/11/2016
phs000888 A cohort study exploring the genetic determinants of more than 40 individual phenotypes (case/control sets included). N= 55,029. Imputation 08/11/2016
phs001011 Case/control cohort study of data from participants enrolled across six cohorts at Cincinnati Children’s Hospital. N= 1,568. Whole Exome & Genome Genotyping 09/27/2016
phs001191 Longitudinal cohort study from Northwestern University’s NUgene project containing whole genome sequencing data. N= 900. Whole Genome Sequencing 10/03/2017
phs000906 Cohort study exploring clinical implementation of pharmacogenomics sequence data. N= 9,010. Targeted Genomic Sequencing 12/06/2017
phs001165 Longitudinal cohort study from the Children’s Hospital of Philadelphia containing whole genome sequencing data. N= 900. Whole Genome Sequencing 05/25/2018
phs000234 Case/control study focusing on dementia participants. N= 3,756. Whole Genome Genotyping 05/30/2018
phs001616 eMERGE Network Phase III Clinical Sequencing: eMERGEseq panel. Cohort study exploring phenotypic implications in a custom designed eMERGEseq Freeze 1 Dataset consisting of 109 genes and 1400 SNPs. N=15,700. Targeted Genomic Sequencing 05/01/2019
phs001584.v1.p1 eMERGE Network Phase III: HRC Imputed Array Data of 83,000+ Participants. Imputation 07/11/2019
In the News

Here's what's happening with eMerge:

01
JUL

Read the full press release here. Congratulations to all the sites in the next round of eMERGE! The new clinical sites will be led by: Iftikhar J. Kullo, M.D., at Mayo Clinic, Rochester, Minnesota Dan M. Roden, M.D., at Vanderbilt University Medical Center, Nashville, Tennessee Elizabeth W. Karlson, M.D., at Brigham and Women’s Hospital, Boston Rex […]

08
MAY

The eMERGE Network is excited to share that the MCS NT304, Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in the eMERGE Network; was published on May 7th to American Journal of Human Genetics.

24
MAR

Two companion RFAs for the PRS Diversity Consortium are now published: Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry – Study Sites (U01 Clinical Trial Not Allowed): https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-001.html Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry – Coordinating Center (U01 Clinical Trial Not Allowed): https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-002.html The goal […]

27
FEB

Notice to Encourage Eligible NHGRI Awardees to Apply for PA-18-906 “Research Supplements to Promote Diversity in Health-Related Research” https://grants.nih.gov/grants/guide/notice-files/NOT-HG-19-010.html PIs of active NHGRI research grants can apply; identify eligible individuals, including those from underrepresented groups, for support and mentorship under the auspices of this supplement opportunity. Supplement can support individuals from the undergraduate to the […]